Refurbish Life Sciences is researching and developing innovative new drug anticancer drugs and has a variety of new drug candidates ranging from third-generation immunotherapy drugs to fourth-generation cancer drugs.
Pipeline
Pipeline
Discorvery
Pre-Clinical
Clinical
Project
Indication
EarlyLate
Small Molecule
YRP-1
Brain cancer glioblastoma
2019: Efficacy Effectiveness: In the first half of 2020: Clinical drug, toxicity studyFrom 2019 to 2020: Preclinical
2020: The goal of the Phase 1 clinical trial approach.
Indication enlargement
2021: The goal of the Phase 2 clinical trial approach.
SRP-1
Brain cancer glioblastoma identification patent
Candidate
DRP-1
Patent for blood pressure medicine/ breast cancer indication effect